Table 1.
Clinicopathological, immunohistochemical, and treatment characteristics for 253 patients aged more than 65 diagnosed with oestrogen receptor positive, clinically lymph node negative breast cancer.
| Clinicopathological, immunohistochemical and treatment characteristics | ||
|---|---|---|
| Age at diagnosis (years) | Mean ± SD (range); median | 73.2 ± 5.5 (66-90); 72 |
| Aged 66-70 | 99 (39.1%) | |
| Aged 71-75 | 75 (29.7%) | |
| Aged > 75 | 79 (31.2%) | |
| Histological tumour type | Invasive ductal carcinoma | 203 (80.2%) |
| Invasive lobular carcinoma | 42 (16.6%) | |
| Other (mucinous, micropapillary, papillary, tubular, tubulolobular, etc) | 8 (3.2%) | |
| Tumour size (mm) | Mean ± SD (range), median | 22.7 ± 10.5 (1-50), 22 |
| Tumour stage | T1 | 121 (47.8%) |
| T2 | 132 (52.2%) | |
| Tumour grade | 1 | 15 (5.9%) |
| 2 | 204 (80.6%) | |
| 3 | 34 (13.4%) | |
| Lymphovascular invasion, n (%) | Present | 43 (17.0%) |
| Absent | 210 (83.0%) | |
| ER score | Mean ± standard deviation (range), median | 7.8 ± 0.1, 8 |
| PgR status PgR score | Positive | 214 (84.6%) |
| Negative | 39 (15.4%) | |
| Mean ± standard deviation (range), median | 5.6 ± 2.1, 7 | |
| Ki67 proliferation index (%) (n = 42) | Mean ± standard deviation (range), median | 13.6 ± 1.7, 10 |
| Primary surgery | Breast conserving surgery | 219 (86.6%) |
| Mastectomy | 34 (13.4%) | |
| SLNB SLNB nodal yield | Underwent SLNB | 253 (100.0%) |
| Did not undergo SLNB | 0.0 (0.0%) | |
| Median ± standard deviation (range) | 3.0 ± 2.5 (1-12) | |
| OncotypeDX score (n = 82, 32.4%) | Score Mean ± standard deviation (range), median | 17.8 ± 9.8 (1-44) |
| Low risk (0-10) | 13 (15.9%) | |
| Intermediate risk (11-25) | 51 (62.2%) | |
| High risk (> 25) | 18 (22.0%) | |
| Adjuvant endocrine therapy | Yes | 253 (100.0%) |
| No | 0.0 (0.0%) | |
| Adjuvant chemotherapy | Yes | 51 (20.2%) |
| No | 202 (79.8%) | |
| Adjuvant radiotherapy | Yes | 173 (68.4%) |
| No | 80 (31.6%) | |
| Completion ALND | Yes | 19 (7.5%) |
| No | 234 (92.5%) | |
Abbreviations: ALND, axillary lymph node dissection; ER, oestrogen receptor; PgR, progesterone receptor; SD, standard deviation; SLNB, sentinel lymph node biopsy.